Management of early stage chronic myeloid leukemia: State-of-the-art approach and future perspectives

Federica Galaverna, Chiara Ghiggi, Fabio Guolo, Germana Beltrami, Clara Dellepiane, Livia Giannoni, Andrea Carella, Angelo M. Carella

Research output: Contribution to journalArticlepeer-review


Tyrosin Kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-tonormal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15% of all patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for treating, and possibly curing, CML in the upcoming years.

Original languageEnglish
Pages (from-to)749-754
Number of pages6
JournalCurrent Cancer Drug Targets
Issue number7
Publication statusPublished - 2013


  • Chronic myeloid leukemia
  • New therapeutic strategies
  • Stem cell biology
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Management of early stage chronic myeloid leukemia: State-of-the-art approach and future perspectives'. Together they form a unique fingerprint.

Cite this